Loading patent…
AssigneesEuropean Molecular Biology Laboratory, Fahy Gurteen Laboratories Ltd., UCL Business PLC
InventorsJan Ellenberg, Beate Neumann, Marco Loddo, Gareth Williams, Kai Stoeber
Estimating the term…
The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease. The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.
A method for determining the risk of progression of a proliferative lesion to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced level compared to a control, there is the risk of progression to invasive cancer and/or risk of recurrent disease.
A method for determining the risk of progression of a proliferative lesion to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence of loss of function-related genetic alterations in the PAPPA gene or its regulatory or promoter sequences in a sample obtained from the patient, wherein if genetic alterations are present there is the risk of progression to invasive cancer and/or risk of recurrent disease.
A method for determining the risk of progression of a proliferative lesion to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising identifying the proportion of mitotic cells in a breast tissue sample obtained from the patient that are in prophase or pro-metaphase and comparing to a pre-determined cut-off value, wherein if the proportion of cells in prophase or pro-metaphase is greater than the cut-off value there is risk of progression to invasive breast cancer and/or risk of recurrent disease.
(canceled)
A therapeutic regimen for treating or preventing breast cancer in a patient, comprising:
A chemotherapeutic agent that targets molecular events during cell division, for use in the treatment or prevention of breast cancer, wherein the chemotherapeutic is to be administered to a patient who has been prior treated with a molecule that releases a cell from mitotic delay.
Dependencies are inferred from the claim text.